Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference
February 08, 2022 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 25, 2022 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
January 13, 2022 07:00 ET
|
Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
January 04, 2022 07:00 ET
|
Gritstone bio
-- Single 10 µg dose of samRNA vaccine containing Spike plus additional T cell epitopes (TCE) induced robust neutralizing antibody titers in ten healthy adults ≥60yrs who had received two prior doses...
Gritstone Announces Presentations during Three Upcoming Investor Conferences
December 30, 2021 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Changes to Its Board of Directors
December 17, 2021 07:00 ET
|
Gritstone bio
-- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1,...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2021 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone bio Added to the Nasdaq Biotechnology Index
December 13, 2021 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant
December 06, 2021 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif. and OSLO, Norway, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious...
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines
November 29, 2021 07:00 ET
|
Gritstone bio
Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone’s COVID-19 vaccines (CORAL program) T cell immunity...